RG002-04
HPV-associated HSIL / Persistent Infection / Cancer
PreclinicalActive
Key Facts
Indication
HPV-associated HSIL / Persistent Infection / Cancer
Phase
Preclinical
Status
Active
Company
About RinuaGene Biotechnology
A clinical-stage biotech developing mRNA therapeutics and vaccines with a proprietary platform, targeting HPV-related diseases, rare conditions, and infectious diseases.
View full company profileTherapeutic Areas
Other HPV-associated HSIL / Persistent Infection / Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| RG002 (RG002-01) | RinuaGene Biotechnology | Phase 1/IIa |
| RG002-02 | RinuaGene Biotechnology | Preclinical |